

REMARKS

Upon entry of this Preliminary Amendment, original claims 1-25 have been cancelled. Claims 26-30 are pending. A priority information sentence has been added to the first line of the specification. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b).

Entry of this amendment into the record is requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Wayne J. Dustman", with a horizontal line extending from the end of the signature.

Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5023
Facsimile: (610) 270-5090
n:\wjd\paroxetine\p31178D7-C1preamend.doc

ABSTRACT OF THE DISCLOSURE

Invented is paroxetine hydrochloride anhydrate in Form B and paroxetine hydrochloride anhydrate in Form D. Also invented are pharmaceutical formulations comprising these compounds and methods of using these compounds in therapy.